高级检索
当前位置: 首页 > 详情页

Substance P Promotes the Progression of Endometrial Adenocarcinoma

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Gynecology, The Fourth Hospital, Hebei Medical University [2]Department of Surgery, Hospital of Hebei Province Crop of Chinese Armed Police Force [3]Department of Traditional Chinese Medicine, The Fourth Hospital, Hebei Medical University, Shijiazhuang, Hebei, China.
出处:
ISSN:

关键词: Substance P NK-1 receptor Endometrial adenocarcinoma VEGF-C MMP-9

摘要:
Objectives: It has been demonstrated that substance P (SP) promotes while neurokinin-1 receptor (NK-1R) antagonist inhibits the proliferation of several human cancer cells. Currently, it is still unknown whether such actions exist in human endometrial carcinoma. This study aimed to explore the role of SP/NK-1R signaling in the progression of endometrial adenocarcinoma. Materials and Methods: The expression levels of SP and NK-1R in endometrial adenocarcinoma tissues and Ishikawa cell line were detected by real-time quantitative PCR and Western blot analysis. The effects of SP on Ishikawa cells proliferation and invasion were analyzed using MTT assay and transwell matrigel invasion assay, respectively. The expression levels of matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor C (VEGF-C) in Ishikawa cells after administration of SP were detected by real-time quantitative RCR and Western blot analysis. Results: The expression levels of SP and NK-1R were significantly higher in endometrial adenocarcinoma tissues and Ishikawa cells than in normal endometrium. Substance P significantly enhanced the proliferation and invasion of Ishikawa cells. In addition, SP induced the expression of MMP-9 and VEGF-C in Ishikawa cells, whereas NK-1R antagonist inhibited these effects. Conclusions: Substance P plays an important role in the development of endometrial carcinoma by inducing the expression of MMP-9 and VEGF-C and promoting cancer cell proliferation and metastasis, which can be blocked by NK-1R antagonist.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 3 区 妇产科学 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 妇产科学 3 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q2 OBSTETRICS & GYNECOLOGY Q3 ONCOLOGY
最新[2024]版:
Q1 OBSTETRICS & GYNECOLOGY Q1 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Department of Gynecology, The Fourth Hospital, Hebei Medical University
通讯作者:
通讯机构: [1]Department of Gynecology, The Fourth Hospital, Hebei Medical University [*1]Department of Gynecology, The Fourth Hospital, Hebei Medical University, Shijiazhuang 050011, Hebei, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号